-
2023-04-25
优锐医药First-in-Class慢阻肺管线中国III期顺利启动，加速推进呼吸特药精耕
动脉网获悉，专注呼吸类创新药的生物医药公司：优锐医药，已经于2023年4月6日完成Ensifentrine ENHANCE - CHINAIII期临床试验的首例患者给药，适用于中国大陆区域慢性阻塞性肺疾病(COPD)疾病的维持治疗。
-
2023-04-24
优锐医药受邀出席中关村肾病血液净化创新联盟 “峥嵘五年 再续华章” 五周年庆典
优锐医药荣获联盟颁发的【企业公益大使形象TOP10】奖项
-
2023-04-11
BAVARIAN NORDIC COMPLETES CASE ACCRUAL FOR RSV PHASE 3 CLINICAL TRIAL
Bavarian Nordic announced Phase 3 clinical trial of MVA-BN® RSV has now accrued the number of cases required to complete the primary efficacy analysis
-
2023-04-06
Ensifentrine Completes Dosing of First Patient in ENHANCE - CHINA Phase III Trial for COPD
SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel
-
2023-03-14
Bentrio™鼻喷剂 活力上线 亮相中国香港！
优锐医药亚太区域首款商业产品，Bentrio™鼻喷剂已在中国香港首发上市！
-
2023-03-03
Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties
Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control
-
2023-02-14
Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting
Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)
-
2023-01-24
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
Altamira Therapeutics Ltd. today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)
Contact PR
